[1] Wetzel SG, Cha S, Law M, et al. Preoperative assessment of intracranial tumors with perfusion MR and a volumetric interpolated examination:a comparative study with DSA. Am J Neuroradiol,2002,23(10):1767-1774.
[2] Lev MH, Hochberg F. Perfusion magnetic resonance imaging to assess brain tumor responses to new therapies. Cancer Control J,1998, 5(2):115-123.
[3] Benard F, Romsa J, Hustinx R. Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Semin Nucl Med, 2003, 33(2):148-162.
[4] Kracht LW, Miletic H, Busch S, et al. Delineation of brain tumor extent with[11C] L-methionine positron emission tomography:local comparison with stereotactic histopathology. Clin Cancer Res, 2004,10(21):7163-7170.
[5] Grosu A L, Weber W, Feldmann H J, et al. First experience with I-123-alpha-methyl-tyrosine speet in the 3-D radiation treatment planning of brain gliomas. Int J Radiat Oncol Biol Phys, 2000, 47(2):517-526.
[6] Padma MV, Said S, Jacobs M, et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol, 2003, 64(3):227-237.
[7] Yokogami K, Kawano H, Moriyama T, et al. Application of SPECT using 99mTcO4-MIBI in brain tumors and comparison with expression of the MDR-lgene:is it possible to predict the response to chemotherapy in patients with gliomas by means of 99mTcO4-MIBI SPECT?. Eur J Nucl Med, 1998, 25(2):401-409.
[8] Giammarile F, Houzard C, Bournaud C, et al. High and low grade oligodendrogliomas (ODG):correlation of amino-acid and glucose uptakes using PET and histological classifications. J Neurooncol,2004, 68(3):263-274.
[9] Al-Hallaq HA, Zamora M, Fish BL, et al. MRI measurements correctly predict the relative effects of tumor oxygenating agents on hypoxic fraction in rodent BA1112 tumors. Int J Radiat Oncol Biol Phys, 2000, 47(3):481-488.
[10] Alber M, Paulsen F, Eschmann SM, et al. On biologically conformal boost dose optimization. Phys Meal Biol, 2003, 48(2):31-35.
[11] Chao KSC, Bosch WR, Mutic S, et al. A novel approach to overcome hypoxic tumor resistance:Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys, 2001, 49(4):1171-1182.
[12] Chen W, Cloughesy T, Kamdar N, et al. Imaging proliferation in brain tumors with 18F-FLT PET:comparison with 18F-FDG. J Nucl Med, 2005, 46(6):945-952.
[13] Fuss M, Wenz F, Essig M, et al. Tumor angiogenesis of low-grade astrocytomas measured by dynamic susceptibility contrast-enhanced MRI (DSC-MRI) is predictive of local tumor control after radiation therapy. Int J Radiat Oncol Biol Phys, 2001, 51(2):478-482,.
[14] Haubner R, Wester HJ, Weber WA, et al. Non-invasive imaging of αvβ3 integrin expression using a 18F-labeled RGD-containing glycopoptide and positron emission tomography. Cancer Res, 2001,61(5):1781-1785.